EMEA-001373-PIP01-12-M03

Key facts

Invented name
Mysimba
Active substance
  • Naltrexone (hydrochloride)
  • bupropion (hydrochloride)
Therapeutic area
Other
Decision number
P/0365/2017
PIP number
EMEA-001373-PIP01-12-M03
Pharmaceutical form(s)
Prolonged-release tablet
Condition(s) / indication(s)
Treatment of obesity
Route(s) of administration
Oral use
Contact for public enquiries
Orexigen Therapeutics Ireland Limited
Tel. +1 8588758600
E-mail: ir@orexigen.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating